Gonadotrophin-releasing hormones agonist therapy increases peritoneal fibrinolytic activity and prevents adhesion formation after myomectomy.
The aim of this study was to evaluate uterine adhesions after myomectomy and peritoneal fibrinolytic capacity in women treated with gonadotrophin-releasing hormone agonist (GnRHa) before surgery. A prospective observational study comprised 15 infertile women who underwent myomectomy. Before surgery, 10 were treated with buserelin acetate (900 microg/day) for 10-12 weeks followed by additional postoperative treatment with GnRHa for 4 weeks (GnRHa group) and five received no treatment (control group). Peritoneal fluid specimens were taken at the beginning of myomectomy and the adhesions were estimated by second-look surgery (caesarean section or laparoscopy). Levels of plasminogen activator (PA) and PA inhibitor (PAI) were determined by enzyme-immunosorbent assays. Pre- and postoperative GnRHa therapy significantly reduced adhesion formation compared with control groups (adhesion scores; 0.2 +/- 0.4 vs. 2 +/- 1, P<0.0001). GnRHa group showed a significant decrease in PAI level (P<0.0001) but no significant change in PA level, suggesting increased fibrinolytic capacity in peritoneal fluid from GnRHa-treated patients. These data suggest that GnRHa therapy is successful in preventing adhesion formation after myomectomy. GnRHa-induced shift to more fibrinolytic activity, mainly because of a decreased level of PAI, may play a critical role in the mechanism of the GnRHa's action on postoperative adhesion development.
Imai
A
A
Department of Obstetrics and Gynaecology, Gifu University School of Medicine, Japan. atsushi@cc.gifu-u.ac.jp
Sugiyama
M
M
Furui
T
T
Takahashi
S
S
Tamaya
Teruhiko
T
D000328:Adult; D002064:Buserelin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000601:surgery*; D010532:Peritoneal Diseases / Q000473:pathology / Q000517:prevention & control*; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D010960:Plasminogen Activators / Q000097:blood; D011183:Postoperative Complications / Q000517:prevention & control; D011292:Premedication; D011446:Prospective Studies; D024162:Second-Look Surgery; D012720:Severity of Illness Index; D000267:Tissue Adhesions / Q000473:pathology / Q000517:prevention & control*; D016896:Treatment Outcome
D017395:Plasminogen Activator Inhibitor 1; D010960:Plasminogen Activators; D002064:Buserelin